

CITATION REPORT

List of articles citing

Effect of acute testosterone on myocardial ischemia in men with coronary artery disease

DOI: 10.1016/s0002-9149(98)00880-7

American Journal of Cardiology, 1999, 83, 437-9, A9.

Source: <https://exaly.com/paper-pdf/30565956/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
210	Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. 1999 , 100, 1690-6		373
209	Heart medications: indications and interactions in stress testing. 1999 , 6, 357-61		1
208	Androgen therapy in the aging male: assessing the effect on heart disease. 1999 , 2, 151-156		4
207	Androgen deficiency in aging men: role of testosterone replacement therapy. 2000 , 135, 370-8		64
206	Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. <i>American Journal of Cardiology</i> , 2000 , 85, 269-72	3	118
205	Rapid, nongenomic steroid actions: A new age?. 2000 , 21, 57-94		127
204	Gonadal hormones affect diameter of male rat cerebral arteries through endothelium-dependent mechanisms. 2000 , 279, H610-8		68
203	Androgens and the risk of cardiovascular disease. 2000 , 3, 190-5		8
202	Nongenomic actions of steroids--from the laboratory to clinical implications. 2000 , 13, 853-78		14
201	Testosterone: a natural tonic for the failing heart?. 2000 , 93, 689-94		32
200	Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. 2000 , 102, 1906-11		492
199	Cardiovascular risk factors in men: The role of gonadal steroids and sex hormone-binding globulin. 2001 , 50, 882-8		77
198	Androgens and aging. 2001 , 38, 61-71; discussion 71-3		121
197	Vascular effects of hormones. 2001 , 38, 45-50; discussion 50-1		10
196	Effect of sex hormones on cardiac mass. 2001 , 357, 1354-6		80
195	Testosterone and cardiovascular diseases. 2001 , 297-332		5
194	Esterified estrogens combined with methyltestosterone improve emotional well-being in postmenopausal women with chest pain and normal coronary angiograms. 2001 , 8, 233-8		25

193	Was ist gesichert in der Diagnostik und Therapie des partiellen Androgendefizits (PADAM)? 2001 , 41, 325-330	1
192	Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. 2001 , 98, 3589-93	200
191	The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. 2001 , 86, 4867-73	108
190	[Androgen deficiency in older men--what happens with testosterone substitution?]. 2001 , 126, 247-52	3
189	Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. 2001 , 86, 1026-33	47
188	The effects of cardiopulmonary bypass on androgen hormones in coronary artery bypass surgery. 2002 , 30, 9-14	5
187	Vascular reactivity in hypogonadal men is reduced by androgen substitution. 2002 , 87, 5030-7	69
186	Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. 2002 , 57, M460-5	63
185	Consensus Document on substitution therapy with testosterone in hypoandrogenic elderly men. 2002 , 14, 439-64	7
184	Andropause: clinical implications of the decline in serum testosterone levels with aging in men. 2002 , 57, M76-99	300
183	Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. 2002 , 143, 249-56	44
182	Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. <i>American Journal of Cardiology</i> , 2002 , 89, 862-4	3 94
181	Intrinsic responses of rat coronary arteries in vitro: influence of testosterone, calcium, and effective transmural pressure. 2002 , 19, 155-61	8
180	Testosterone supplementation therapy for older men: potential benefits and risks. 2003 , 51, 101-15; discussion 115	217
179	Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. 2003 , 58, 632-8	242
178	The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men. 2003 , 59, 749-55	57
177	The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action?. 2003 , 138, 733-44	102
176	Free testosterone plasma levels are negatively associated with the intima-media thickness of the common carotid artery in overweight and obese glucose-tolerant young adult men. 2003 , 27, 803-7	53

175	In vitro effects of progesterone and progestins on vascular cells. 2003 , 68, 831-831	
174	Andropause: an old concept in new clothing. 2003 , 19, 507-28	25
173	Male hypogonadism in the primary care clinic. 2003 , 30, 743-63, vii	9
172	In vitro effects of progesterone and progestins on vascular cells. 2003 , 68, 831-6	37
171	Can testosterone replacement decrease the memory problem of old age?. 2003 , 60, 893-6	8
170	Testosterone and atherosclerosis. 2003 , 13 Suppl A, S72-84	40
169	Cytomegalovirus seropositivity, infectious burden, and coronary artery disease. 2003 , 145, e11	1
168	Androgens and cardiovascular disease. 2003 , 24, 313-40	579
167	Cardiovascular effects of testosterone: implications of the "male menopause"?. 2003 , 89, 121-2	31
166	Androgens and coronary artery disease. 2003 , 24, 183-217	486
165	Testosterone and atherosclerosis progression in men. 2003 , 26, 1929-31	10
164	Cystic tumour of the atrioventricular node. 2003 , 89, 122	10
163	Recommended testing in patients with low bone density. 2003 , 88, 1404-5; author reply 1405	4
162	Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. 2003 , 88, 1402; author reply 1402	8
161	Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: further supportive data. 2003 , 88, 1403-4; author reply 1404	13
160	Efficacy of teriparatide and alendronate on nonvertebral fractures. 2003 , 88, 1402-3; author reply 1403	1
159	Acute haemodynamic effects of testosterone in men with chronic heart failure. 2003 , 24, 909-15	126
158	Authors' Response: Hyperglycemia An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed Diabetes. 2003 , 88, 1402-1402	1

157	Recommended Testing in Patients with Low Bone Density. 2003 , 88, 1404-1404	10
156	Risks and benefits of hormone replacement therapy in older men. 2004 , 59, 32-8	1
155	Testosterone replacement therapy: current trends and future directions. 2004 , 10, 409-19	161
154	Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-kappaB-dependent pathway. 2004 , 145, 1889-97	119
153	Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. 2004 , 90, 871-6	183
152	Endogenous testosterone increases L-type Ca ²⁺ channel expression in porcine coronary smooth muscle. 2004 , 287, H2091-8	43
151	Age-related changes in testosterone and the role of replacement therapy in older men. 2004 , 60, 653-70	100
150	Testosterone metabolism and replacement therapy in patients with end-stage renal disease. 2004 , 17, 202-8	37
149	[The heart and androgens]. 2004 , 65, 163-70	6
148	Hormonal fountains of youth. 2004 , 20, 275-92	18
147	Treatment of hypogonadism in men with chronic kidney disease. 2004 , 11, 348-356	20
146	The aging male: testosterone deficiency and testosterone replacement. An up-date. 2004 , 173, 157-69	36
145	Depression in aging men: the role of testosterone. 2004 , 21, 361-76	43
144	Testosterone as a modulator of vascular behavior. 2004 , 5, 276-85	37
143	Treatment of androgen deficiency in the aging male. 2004 , 81, 1437-40	13
142	Treatment of androgen deficiency in the aging male. 2004 , 82 Suppl 1, S46-50	1
141	Anti-aging medicine: hormone replacement therapy in men. 2004 , 113, 1506-10	0
140	Testosterone-induced coronary vasodilatation occurs via a non-genomic mechanism: evidence of a direct calcium antagonism action. 2004 , 107, 149-58	67

- 139 Cardiovascular membrane excitability and the influence of sex and sex steroids. **2004**, 105-114
- 138 Therapeutic dilemmas for androgen deficiency in aging males. **2005**, 1, 157-166 2
- 137 Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women. **2005**, 45, 177-84 24
- 136 Andropause: is the emperor wearing any clothes?. **2005**, 6, 77-84 15
- 135 Role of endogenous testosterone in myocardial proinflammatory and proapoptotic signaling after acute ischemia-reperfusion. **2005**, 288, H221-6 99
- 134 Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. **2005**, 152, 285-91 38
- 133 The relationship between risk factors and testosterone-induced relaxations in human internal mammary artery. **2005**, 45, 4-7 19
- 132 Testosterone relaxes human internal mammary artery in vitro. **2005**, 45, 580-5 51
- 131 Advances in male hormone substitution therapy. **2005**, 6, 1493-506 18
- 130 Testosterone and atherosclerosis in aging men: purported association and clinical implications. **2005**, 5, 141-54 86
- 129 Treatment of androgen deficiency in the aging male. **2006**, 86, S236-40 7
- 128 Cardiovascular effects of androgen depletion and replacement therapy. **2006**, 67, 1126-32 5
- 127 Cardiovascular effects of androgens. **2002**, 20, 175-98 40
- 126 The androgen receptor gene CAG repeat polymorphism does not predict increased risk of heart disease: longitudinal results from the Massachusetts Male Ageing Study. **2006**, 65, 333-9 17
- 125 Low testosterone levels are associated with carotid atherosclerosis in men. **2006**, 259, 576-82 131
- 124 Cytochrome P450 enzymes: central players in cardiovascular health and disease. **2006**, 112, 564-87 134
- 123 Selective inhibition of L-type Ca²⁺ channels in A7r5 cells by physiological levels of testosterone. **2006**, 147, 2675-80 90
- 122 Low serum testosterone and mortality in male veterans. **2006**, 166, 1660-5 357

121	Role of endogenous androgen against insulin resistance and atherosclerosis in men with type 2 diabetes. 2007 , 3, 25-31		23
120	Low testosterone levels are associated with coronary artery disease in male patients with angina. <i>International Journal of Impotence Research</i> , 2007 , 19, 176-82	2,3	128
119	Vasodilating mechanisms of testosterone. 2007 , 115, 1-6		61
118	Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. 2007 , 39, 366-71		62
117	Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. 2007 , 116, 2694-701		596
116	Testosterone relaxes isolated human radial artery by potassium channel opening action. 2007 , 103, 309-16		54
115	The association between androgen levels and premature coronary artery disease in men. 2007 , 18, 159-62		24
114	Non-classical actions of testosterone: an update. 2007 , 18, 371-8		158
113	Safety of testosterone treatment in postmenopausal women. 2007 , 88, 1-17		92
112	Déficit androgénico y síndrome metabólico. 2007 , 5, 241-247		
111	Why men's hearts break: cardiovascular effects of sex steroids. 2007 , 36, 365-77		42
110	Hypogonadism in men with type 2 diabetes. 2007 , 24, 269-277		6
109	Are the adverse effects of glitazones linked to induced testosterone deficiency?. 2008 , 7, 30		13
108	Cardiovascular effects of testosterone. 2008 , 5, 187-189		2
107	Testosterone reducing cardiovascular risk--looks promising but randomised trials needed. 2008 , 62, 1131-2		2
106	Clinical practice manual for late-onset hypogonadism syndrome. 2008 , 15, 377-88		54
105	Metabolic and cardiovascular effects of androgen deprivation therapy. 2008 , 102, 1509-14		51
104	Rapid actions of androgens. 2008 , 29, 182-98		128

103	Effects of testosterone on antioxidant systems in male secondary hypogonadism. 2008 , 29, 622-9	50
102	Mechanisms involved in testosterone-induced vasodilatation in pig prostatic small arteries. 2008 , 83, 569-73	37
101	A case of 45,X male: genetic reevaluation and hormonal and metabolic follow-up in adult age. 2008 , 90, 2011.e17-21	6
100	Androgen deficiency in the aging male. 2008 , 90, S83-7	13
99	Testosterone and blood pressure regulation. 2008 , 31, 71-9	87
98	Testosterone and coronary artery disease. 2009 , 37, 91-107	52
97	The brain, the penis and steroid hormones: clinical correlates with endothelial dysfunction. 2008 , 14, 3723-36	15
96	Role of putrescine on androgen-elicited positive inotropism in the left atrium of rats. 2008 , 52, 161-6	8
95	Testosterone for the aging male; current evidence and recommended practice. 2008 , 3, 25-44	89
94	Androgen therapy and atherosclerotic cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2008 , Volume 4, 11-21	4.4 7
93	Testosterone: clinical relevance in ageing men. 2009 , 19, 249-261	1
92	Both endogenous and exogenous testosterone decrease myocardial STAT3 activation and SOCS3 expression after acute ischemia and reperfusion. 2009 , 146, 138-44	29
91	Pulse pressure, an index of arterial stiffness, is associated with androgen deficiency and impaired penile blood flow in men with ED. 2009 , 6, 285-93	54
90	The dark side of testosterone deficiency: III. Cardiovascular disease. 2009 , 30, 477-94	184
89	Cardiovascular Endocrinology. 2009 ,	2
88	The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. 2009 , 207, 318-27	115
87	Role of polyamines and cAMP-dependent mechanisms on 5alpha-dihydrotestosterone-elicited functional effects in isolated right atria of rat. 2009 , 54, 310-8	8
86	Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. 2009 , 16, 1863-87	69

85	Late-onset hypogonadism: Review of the problem. 2010 , 64, 93-97	1
84	Endocrine aspects of male sexual dysfunctions. 2010 , 7, 1627-56	142
83	Gender differences in the cardiovascular effects of sex hormones. 2010 , 24, 675-85	76
82	Pharmacologic targeting of endothelial progenitor cells. 2010 , 10, 16-32	9
81	Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/akt pathway. 2010 , 151, 1822-8	85
80	Hormones and antioxidant systems: role of pituitary and pituitary-dependent axes. 2010 , 33, 422-33	32
79	Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. 2010 , 142, 50-5	54
78	Cardiovascular disease and androgens: a review. 2010 , 142, 8-14	56
77	Testosterone deficiency: a risk factor for cardiovascular disease?. 2010 , 21, 496-503	124
76	Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. 2011 , 165, 687-701	305
75	Hormone replacement therapy in the geriatric patient: current state of the evidence and questions for the future--estrogen, progesterone, testosterone, and thyroid hormone augmentation in geriatric clinical practice: part 2. 2011 , 27, 561-75	2
74	Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. 2011 , 34, 1669-75	234
73	Increased adiposity in DNA binding-dependent androgen receptor knockout male mice associated with decreased voluntary activity and not insulin resistance. 2011 , 301, E767-78	55
72	Mechanisms involved in testosterone-induced relaxation to the pig urinary bladder neck. 2012 , 77, 394-402	14
71	Hormonal effects on blood vessels. 2012 , 35, 363-9	17
70	Medical Therapy for Chronic Refractory Angina. 2012 , 39-51	
69	The hypoxic testicle: physiology and pathophysiology. 2012 , 2012, 929285	113
68	Testosterone and cardiovascular disease in men. 2012 , 14, 428-35	58

67	Testosterone and cardiovascular disease. 207-234	2
66	Chest Pain with Normal Coronary Arteries. 2013 ,	2
65	Testosterone and cardiovascular risk. 2013 , 8 Suppl 1, S65-9	43
64	Androgens and the cerebrovasculature: modulation of vascular function during normal and pathophysiological conditions. 2013 , 465, 627-42	22
63	Antagonist molecules in the treatment of angina. 2013 , 14, 2323-42	9
62	Effect of normobaric hypoxia on the testis in a murine model. 2013 , 45, 332-8	15
61	Androgen Deficiency and Testosterone Replacement. 2013 ,	2
60	Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. 2013 , 2, e000272	131
59	Testosterone: a vascular hormone in health and disease. 2013 , 217, R47-71	164
58	Effect of testosterone undecanoate on hematological profiles, blood lipid and viscosity and plasma testosterone level in castrated rabbits. 2013 , 7, E221-5	15
57	Human androgen deficiency: insights gained from androgen receptor knockout mouse models. 2014 , 16, 169-77	29
56	Controversies in Diagnosis and Treatment of Hypogonadism. 2014 , 6, 89-93	
55	Central serous chorioretinopathy in patients receiving exogenous testosterone therapy. 2014 , 34, 2128-32	20
54	Testosterone replacement and cardiovascular safety: no straight and narrow!. 2015 , 9, 33-7	2
53	Testosterone Replacement Therapy and Cardiovascular Risk: A Review. 2015 , 33, 130-42	34
52	Hypogonadism and Testosterone Therapy: Associations With Cardiovascular Risk. 2015 , 9, 340-4	2
51	Testosterone therapy and cardiovascular risk: advances and controversies. 2015 , 90, 224-51	137
50	The practical management of testosterone deficiency in men. 2015 , 12, 641-50	41

49	Reactive oxygen species: players in the cardiovascular effects of testosterone. 2016 , 310, R1-14	40
48	Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?. 2016 , 8, 118-29	39
47	Androgen receptor (AR) in cardiovascular diseases. 2016 , 229, R1-R16	38
46	Testosterone rapidly increases Ca-activated K currents causing hyperpolarization in human coronary artery endothelial cells. 2017 , 168, 118-126	10
45	Androgen supplementation improves some but not all aspects of immune senescence in aged male macaques. 2017 , 39, 373-384	13
44	Role of Testosterone in the Treatment of Cardiovascular Disease. 2017 , 12, 83-87	7
43	Erectile dysfunction, metabolic syndrome, and cardiovascular risks: facts and controversies. 2017 , 6, 28-36	29
42	How to Prevent Cardiovascular Disorders: Influence of Gonadal Steroids on the Heart. 2018 , 195-201	2
41	Testosterone and Cardiovascular Health. 2018 , 93, 83-100	49
40	Randomized controlled trials - mechanistic studies of testosterone and the cardiovascular system. 2018 , 20, 120-130	35
39	Testosterone, myocardial function, and mortality. 2018 , 23, 773-788	19
38	An update on heart disease risk associated with testosterone boosting medications. 2019 , 18, 321-332	11
37	Geometric, elastic and contractile-relaxation changes in coronary arterioles induced by Vitamin D deficiency in normal and hyperandrogenic female rats. 2019 , 122, 78-84	6
36	Testosterone deficiency in men with Type 2 diabetes: pathophysiology and treatment. 2020 , 37, 174-186	21
35	Hypogonadism and its treatment following ischaemic stroke in men with type 2 diabetes mellitus. 2020 , 23, 71-80	15
34	Increased Medical Complications, Revisions, In-Hospital Lengths of Stay, and Cost in Patients With Hypogonadism Undergoing Primary Total Knee Arthroplasty. 2020 , 35, 95-99	4
33	Late-onset hypogonadism: Reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy. 2020 , 8, 1614-1627	7
32	Hypogonadism management and cardiovascular health. 2020 , 132, 35-41	1

31	Testosterone therapy and cardiovascular diseases. 2021 ,	4
30	Microvessel Density: Integrating Sex-Based Differences and Elevated Cardiovascular Risks in Metabolic Syndrome. 2021 , 1-15	1
29	Nonhuman Primate Models of Immunosenescence. 2018 , 1-28	1
28	Treatment of stable angina. 1999 , 14, 349-58	29
27	Treatment of Men for "Low Testosterone": A Systematic Review. 2016 , 11, e0162480	61
26	Testosterone and the Heart. 2017 , 13, 68-72	35
25	Testosterone and the Heart. 2019 , 14, 103-110	24
24	Study of androgen and atherosclerosis in old-age male. 2005 , 6, 931-5	19
23	Potential approaches to enhance the effects of estrogen on senescent blood vessels and postmenopausal cardiovascular disease. 2010 , 8, 29-46	14
22	Testosterone and Cardiovascular Disease. 2016 , 10, 1-10	12
21	Androgen Deficiency in Aging Males and Healthy Aging. 2001 , 103-115	
20	Der alternde Mann. 2001 , 41-85	
19	Androgens and Coronary Artery Disease. 2002 , 361-386	
18	Androgen Treatment of the Hypogonadal Male. 2003 , 313-334	
17	Androgens and Coronary Artery Disease. 2003 , 191-220	
16	Androgens in Older Men. 2003 , 347-364	
15	Hormonwirkungen und Hormontherapie. 2004 , 29-80	
14	Erectile Dysfunction. 2009 , 519-526	

13	Testosterone and Its Association with Metabolic and Cardiovascular Disease. 2013 , 55-72		
12	Hormonal Changes in Cardiac Syndrome X Role of Testosterone. 2013 , 303-307		
11	Hormone Replacement Therapy with Testosterone. 2013 , 1-19		
10	Hormone Replacement Therapy with Testosterone and the Vascular System. 2015 , 4681-4693		
9	Nonhuman Primate Models of Immunosenescence. 2019 , 125-152		
8	Testosterone and Cardiovascular Disease. 2009 , 187-197		
7	Testosterone replacement in men with andropause: an overview. <i>Reviews in Urology</i> , 2004 , 6 Suppl 6, S9-S15	1	6
6	The androgen-deficient aging male: current treatment options. <i>Reviews in Urology</i> , 2003 , 5 Suppl 1, S22-8		5
5	Androgen therapy and atherosclerotic cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2008 , 4, 11-21	4.4	9
4	Androgen Receptor Structure, Function and Biology: From Bench to Bedside. <i>Clinical Biochemist Reviews</i> , 2016 , 37, 3-15	7.3	185
3	Testosterone replacement therapy and cardiovascular disease.. <i>International Journal of Impotence Research</i> , 2022 ,	2.3	0
2	Testosterone and cardiovascular disease - a literature review. <i>Scripta Scientifica Medica</i> , 2022 , 54, 9	0.1	
1	A Review of Testosterone Supplementation and Cardiovascular Risk. 2022 ,		0